Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $5.88.
A number of brokerages have issued reports on CNTB. HC Wainwright reiterated a “buy” rating on shares of Connect Biopharma in a report on Wednesday, October 28th. Leerink Partners started coverage on shares of Connect Biopharma in a research note on Monday, October 12th. They issued an “outperform” rating and a $4.00 price target on the stock. Oppenheimer cut their price objective on Connect Biopharma to $5.00 and set an “outperform” rating for the company in a research report on Tuesday, September 22nd. Canaccord Genuity Group reduced their target price on Connect Biopharma from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, September 16th. Finally, BTIG Research decreased their target price on Connect Biopharma to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th.
Check Out Our Latest Research Report on Connect Biopharma
Hedge Funds Weigh In On Connect Biopharma
Institutional investors have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC purchased a new stake in shares of Connect Biopharma during the 1st quarter worth approximately $1,945,000. BML Capital Management LLC boosted its position in shares of Connect Biopharma by 574.1% during the 3rd quarter. BML Capital Management LLC now owns 3,864,400 shares of the company’s stock valued at $4,251,000 after acquiring an additional 3,291,113 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Connect Biopharma by 12.0% during the 3rd quarter. Marshall Wace LLP now owns 376,029 shares of the company’s stock valued at $414,000 after acquiring an additional 40,387 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Connect Biopharma in the first quarter valued at $41,000. Finally, Knott David M Jr grew its holdings in shares of Connect Biopharma by 93.9% in the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after purchasing an additional 187,835 shares in the last quarter. Hedge funds and other institutional investors own 58.72% of the company’s stock.
Connect Biopharma Price Performance
CNTB stock opened at $0.68 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.37. The company’s fifty day moving average price is $1.04 and its 200-day moving average price is $2.11. Connect Biopharma has a one year low of $0.64 and a one year high of $3.82. The company has a market capitalization of $42.65 million, a PE ratio of -0.57 and a beta of 0.06.
About Connect Biopharma
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
Further Reading
- Five stocks we like better than Connect Biopharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
